Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Carbimazole embryopathy is a recently recognized and defined phenotype. Choanal atresia; gastrointestinal anomalies, particularly esophageal atresia; athelia or hypothelia; developmental delay; hearing loss; aplasia cutis; and dysmorphic facial features all can occur after exposure to the antithyroid drugs carbimazole or methimazole during gestation. Although full expression of this phenotype appears to be an uncommon sequelae of antenatal carbimazole exposure, infants with less overt manifestations may remain with the condition undiagnosed. It is clearly important when an infant with choanal atresia is assessed to take an adequate drug history and consider this embryopathy as a potential causative factor.
Wolf D, Foulds N, Daya H. Antenatal Carbimazole and Choanal Atresia: A New Embryopathy. Arch Otolaryngol Head Neck Surg. 2006;132(9):1009–1011. doi:10.1001/archotol.132.9.1009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: